ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an initial focus on the treatment of respiratory syncytial virus (RSV). The company’s lead product candidate, sisunatovir, is an orally administered fusion inhibitor currently being evaluated in two global Phase 2 clinical studies: one in a paediatric patient population and the other in an adult stem-cell transplant patient population. The company also has an N-protein replication inhibitor program in preclinical development.
Today with @pfizer we are proud to announce that we have entered into a definitive agreement under which Pfizer will acquire ReViral and its #RSV Respiratory Syncytial Virus therapeutic candidates. Learn more: reviral.co.uk/investors-medi… pic.twitter.com/yqh5yFIytu
Copyright © 2022 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.